These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29948964)

  • 21. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
    Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q
    Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
    Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
    Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
    Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
    Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison.
    Kharat A; Brendle M; Chhibber A; Chaiyakunapruk N; Biskupiak J
    Oncol Res Treat; 2021; 44(9):476-484. PubMed ID: 34315166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
    Zhang H; Kellett C; Lambert P; Kim CA
    Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
    Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
    Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
    Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
    JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.
    Tam VC; Ko YJ; Mittmann N; Cheung MC; Kumar K; Hassan S; Chan KK
    Curr Oncol; 2013 Apr; 20(2):e90-e106. PubMed ID: 23559890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
    Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
    Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The economic burden of metastatic pancreatic cancer.
    Malangone-Monaco E; Doleh Y; Cole A; Noxon V; Antico G; Pishvaian MJ
    Pancreatology; 2020 Oct; 20(7):1434-1441. PubMed ID: 32967794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
    McBride A; Bonafede M; Cai Q; Princic N; Tran O; Pelletier C; Parisi M; Patel M
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1153-1160. PubMed ID: 28795609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
    Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
    JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?
    Bansback N; Ward S; Karnon J
    Eur J Health Econ; 2004 Jun; 5(2):188-9. PubMed ID: 15452756
    [No Abstract]   [Full Text] [Related]  

  • 39. Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
    Vaccaro V; Sperduti I; Vari S; Bria E; Melisi D; Garufi C; Nuzzo C; Scarpa A; Tortora G; Cognetti F; Reni M; Milella M
    World J Gastroenterol; 2015 Apr; 21(16):4788-801. PubMed ID: 25944992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
    Kurihara T; Kobayashi M; Kogo M; Yoneyama K; Ito N; Sunaga T; Konishi K; Imawari M; Tobe T; Kiuchi Y
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):659-64. PubMed ID: 20414022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.